Vectorized Antibodies by In Vivo Expression of DNA or RNA: A Competitive Business, Stakeholder, Technology and Pipeline Analysis from an Industry Perspective
Ç×üÀÇ »ýü ³» ¹ßÇöÀ» À§ÇÑ ¹ÙÀÌ·¯½º º¤ÅÍ DNA Á¦Ç° Èĺ¸
Ç×üÀÇ »ýü ³» ¹ßÇöÀ» À§ÇÑ ¿ëÇØ¼º ¹ÙÀÌ·¯½º DNA Á¦Ç° Èĺ¸
Ç×üÀÇ »ýü ³» ¹ßÇöÀ» À§ÇÑ ºñ¹ÙÀÌ·¯½º DNA Á¦Ç° Èĺ¸
Ç×üÀÇ »ýü ³» ¹ßÇöÀ» À§ÇÑ RNA Á¦Ç° Èĺ¸
Á¦9Àå Âü°í ¹®Çå
LSH
¿µ¹® ¸ñÂ÷
¿µ¹®¸ñÂ÷
This report provides you with a landscape description and analysis of Vectorized antibodies by in vivo expression of DNA or RNA regarding stakeholders, R&D pipeline, profile & composition of drug candidates and business deals from an industry perspective as of June 2025.
Passive immunotherapy with monoclonal antibodies produced ex vivo mostly in mammalian cell culture systems has become a clinically and commercially successful treatment modality during the last three decades. Despite the clinical success of therapeutic antibodies, they still have limitations including the high cost, caused in great part by manufacturing and control, and the amount of drug needed for repeated administrations at high doses. Development of the manufacturing process as well as commercial scale GMP manufacturing of antibodies in great amounts is a complex process. Other limitiations refer to the inconvenience of frequent administrations associated with an unsatisfactory pharmacokinetic profile, challenging administration procedures to the eye (e.g. subretinal injection) or the central nervous system (e.g. intrathecal infusion with indwelling catheter) or side effects and limited efficacy upon systemic administration without tissue specificity, an important aspect in cancer therapy.
Vectorized antibodies hold promise to overcome many of these limitations and provide a great opportunity for DNA and RNA technology companies to enter larger markets compared with the rare disease indications for which current gene therapies are approved or in development.
In vivo expression of therapeutics antibodies by DNA or RNA may overcome at least some of the limitations of conventional antibody therapy. The antibody transgene may be delivered by viral vectors, by direct injection of plasmid DNA into the muscle followed by electroporation or by molecular formulations, such as lipid nanoparticles, for systemic administration.
Ophthalmic diseases are the lead indication for vectorized antibodies expressed in vivo by viral DNA. Clinical results from phase I and II clinical studies of various anti-VEGF vectorized programs for treatment of wet AMD demonstrated safety and tolerability and stable to improved vision and retinal thickness as well as long-term, durable treatment effects up to 4 years. Three distinct anti-VEGF vectorized antibodies are competing in clinical phase III. Topline results from the first anti-VEGF vectorized antibody are expected in 2026 and may provide clinical validation of one vectorized antibody technology.
The report brings you up-to-date with information about and analysis of:
Stakeholders: companies with technologies in viral DNA, oncolytic virus DNA, non-viral DNA and RNA; service providers and biopharmaceutical partners;
Coroporate profiles of stakeholders: technology, territory, year of foundation, employees, financial situation and highest R&D stage
Partnerships o f vectorized antibody technology companies and biopharmaceutical companies;
Vectorized antibody technologies; viral DNA, oncolytic virus DNA, non-viral DNA (plasmid, molecular formulation, cellular delivery) and RNA;
Compositions of vectorized antibody product candidates: DNA or RNA, delivery method and route of administration;
Pipeline of vectorized antibodies: in ophthalmology, oncology, neurology, infectious disease and other therapeutic areas;
Clinical experience in safety and efficacy with vectorized antibodies;
Molecular, preclinical and clinical profile of vectorized antibodies;
Competitor analysis.
Methodology:
This report evaluates the industry landscape of vectorized antibodies in research and development. The report provides a comprehensive overview of the R&D and partnering activities of pharmaceutical and technology companies in the field of vectorized antibodies by in vivo expression of DNA or RNA. This report is based on the identification and description of corporate stakeholders including biopharmaceutical companies and biotechnology companies. All publicly available information is fully referenced, either with more than 190 scientific references (abstracts, posters, presentations, full paper) or hyperlinks leading to the source of information, such as press releases, corporate presentations, annual reports, SEC disclosures and homepage content.
Who will benefit from the report?
Business development and licensing (BDL) specialists;
Venture capital, private equity and investment managers;
Managers of Big Pharma venture capital firms;
Financial analysts;
CEO, COO and managing directors;
Corporate strategy analysts and managers;
Chief Technology Officer;
R&D Portfolio, Technology and Strategy Management;
Clinical and preclinical development specialists.
Related Companies:
4D Molecular Therapeutics
AbbVie
Accesion Therapeutics
Adverum Biotechnologies
Aegis Life
Akamis Bio
AstraZeneca
Avirmax Biopharma
Be Biopharma
BioInvent
BiomEdit
BioNTech
Capsida Biotherapeutics
Ceva Sante Animale (Ceva Animal Health)
Charles River
Chengdu Kanghong Pharmaceutical Group
Chengdu Origen Biotechnology
China Resource Biopharma (CRBio)
China Resource Biopharma (CRBio)
Clearside Biomedical
Criya Therapeutics
De novo Biotherapeutics
Entos Pharmaceuticals
Frontera Therapeutics
Hopewell Therapeutics
Ikarovec
I-Mab
Immorna
ImmVira
Inovio Pharmaceuticals
Levatio
MeiraGTx Holdings
METiS Pharmaceuticals & METiS Therapeutics
Multiverse Pharma
Nanite
Neuracle Genetics
NuclixBio
Otsuka Pharmaceutical Co
PharmAbcine
PharmAbs
ProBio
Promab Biotechnologies
PulseSight Therapeutics (Eyevensys)
Rampart Bioscience
Regeneron Pharmaceuticals
REGENXBIO
RenBio
Reyon Pharmaceutical
Ring Therapeutics
RNAimmune
Sail Biomedicines
Scout Bio
Shanghai Pharmaceuticals Holding
Shape Therapeutics
Shattuck Labs
Skyline Therapeutics
ST Pharm
Suzhou Abogen Biosciences
Transgene
Vanotech
Vernagen
Vironexis Biotherapeutics
Xiamen Amoytop Biotech
Xuanzhu Biopharma
Table of Contents
Frequent Abbreviations
1. Executive Summary
2. Introduction
3. Stakeholder Analysis
3.1. Overview
3.2. Viral DNA Technology Companies with Vectorized Antibodies
3.3. Non-Viral DNA Technology Companies with Vectorized Antibodies
3.4. RNA Technology Companies with Vectorized Antibodies
3.5. Service Providers with RNA Technology for Vectorized Antibodies
3.6. Partnerships with Licensing and Collaboration Agreements for Vectorized Antibodies
4. Profiles of Stakeholders in Vectorized Antibody Technologies
4.1. Viral Vector DNA Companies
4.1.1. 4D Molecular Therapeutics (4DMT)
4.1.2. Adverum Biotechnologies
4.1.3. Avirmax Biopharma
4.1.4. Capsida Therapeutics
4.1.5. Chengdu Origen Biotechnology
4.1.6. Cirrus Biotherapeutics
4.1.7. Frontera Therapeutics
4.1.8. Ikarovec
4.1.9. Kriya Therapeutics
4.1.10. MeiraGTx Holdings
4.1.11. Neuracle Genetics
4.1.12. Regeneron Pharmaceuticals
4.1.13. REGENXBIO
4.1.14. Ring Therapeutics
4.1.15. Scout Bio (now: Ceva)
4.1.16. Shape Therapeutics
4.1.17. Skyline Therapeutics
4.1.18. VectorY
4.1.19. Vironexis Biotherapeutics
4.1.20. Voyager Therapeutics
4.2. Oncolytic Virus DNA Companies
4.2.1. Accession Therapeutics
4.2.2. Akamis Bio
4.2.3. ImmVira
4.2.4. Transgene
4.3. Non-Viral DNA Companies
4.3.1. Inovio Pharmaceuticals
4.3.2. PharmAbs
4.3.3. PulseSight Therapeutics
4.3.4. RenBio
4.3.5. Entos Pharmaceuticals
4.3.6. Nanite
4.3.7. Rampart Bioscience
4.3.8. Be Biopharma
4.3.9. BiomEdit
4.4. RNA Companies
4.4.1. BioNTech
4.4.2. De novo Biotherapeutics
4.4.3. Hopewell Therapeutics
4.4.4. METiS Pharmaceuticals
4.4.5. RNAimmune
4.4.6. Shattuck Labs
4.4.7. Suzhou Abogen Bioscience
4.4.8. Immorna
4.4.9. Nuclix Bio
4.4.10. Sail Biomedicine
4.5. RNA Service Companies
4.5.1. Charles River
4.5.2. Nutcracker Therapeutics
4.5.3. ProBio
4.5.4. ProMab Biotechnologies
4.5.5. ST Pharm
4.5.6. WuXi AppTec
5. Analysis of Vectorized Antibody Technologies
5.1. Viral Vector DNA Technologies for In Vivo Expression of Antibodies
5.2. Oncolytic Virus DNA Technologies for in vivo Expression of Antibodies
5.3. Non-Viral DNA Technologies for in vivo Expression of Antibodies
5.4. RNA Technologies for in vivo Expression of Antibodies
6. Profiles of Vectorized Antibody Technologies
6.1. Viral Vector DNA Technologies for in vivo Expression of Antibodies